MEDI0562, an agonistic humanized anti-OX40 antibody, demonstrated promising efficacy in a phase I trial conducted in 55 patients with advanced solid tumors, including 26 patients with HNSCC. Here, TNFRSF4 is linked to head and neck squamous cell carcinoma.